<DOC>
	<DOCNO>NCT00826904</DOCNO>
	<brief_summary>The purpose study determine whether unrecognized maternal hyperglycemia postprandial lipemia early late gestation predict excess neonatal adiposity .</brief_summary>
	<brief_title>Regulation Of Maternal Fuel Supply And Neonatal Adiposity</brief_title>
	<detailed_description>Mounting epidemiologic evidence suggest maternal obesity Gestational Diabetes Mellitus ( GDM ) independently influence size birth disease susceptibility later life . A major gap understand fetal programming knowledge whether exposure excess maternal fuel absence frank hyperglycemia impact fetal fat accretion . The investigator hypothesis neonatal adiposity result unrecognized maternal hyperglycemia excess lipid availability gestation , part cause excessive lipolysis white adipose tissue obese woman , subsequently diagnose GDM . In Aim 1 investigator test hypothesis obese woman , later diagnose GDM , increase lipolysis unrecognized hyperglycemia hypertriglyceridemia occur early gestation lean woman , result increase plasma non-esterified fatty acid ( NEFA ) , glycerol , triglyceride ( TGs ) , glucose available fetal metabolism . In Aim 2 investigator test hypothesis fetal adiposity ultrasound neonatal adiposity Dual-energy X-ray Absorptiometry ( DXA ) strongly correlate excess lipid glucose availability obese mother early gestation , regardless GDM status , fast biomarkers neonatal insulin sensitivity correlate neonatal adiposity . In Aim 3 investigator test hypothesis in-vitro suppression lipolysis white adipose tissue correlate excess NEFA TG availability in-vivo predictive neonatal adiposity . The elucidation specific derangement glucose lipid metabolism time gestation mother deliver infant excess adiposity could challenge current screen method entirely redirect treatment target responsible maternal fuel . On public health level , research instrumental investigator understand intrauterine environment may deliver excess glucose and/or lipid fetus contribute genesis pediatric obesity epidemic . Such information may result new treatment strategy pregnant woman normalize fetal growth .</detailed_description>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Fetal Macrosomia</mesh_term>
	<criteria>Age 18 35 yr Pregnant ( 1214 week gestation ) Lean ( BMI 2026 kg/m2 ) Obese ( BMI 3038 kg/m2 ) Age &lt; 18 &gt; 35 yr Preexisting diabetes Chronic medical condition : 1. hypertension , 2. hepatitis , 3 . Human immunodeficiency Virus ( HIV ) , 4 . Thrombophilias , 5 . History : 1. thromboembolism , 2. renal disease , 3. neurologic disease , 4. rheumatologic disorder , 5. gastrointestinal disease , 6. cardiac dysfunction , 7. pulmonary disease Obstetric condition : 1. history stillbirth , 2. severe growth restriction , 3. severe preeclampsia , 4. placental abruption Medications know affect lipid glucose metabolism : 1 . Metformin , 2. glucocorticoid , 3. beta agonist blocker , 4. antihypertensive Use recreational drug , alcohol tobacco .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Fetal programming</keyword>
	<keyword>Fetal macrosomia</keyword>
	<keyword>Fetal health</keyword>
	<keyword>Gestational diabetes</keyword>
	<keyword>Maternal health</keyword>
	<keyword>Maternal obesity</keyword>
</DOC>